Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

Core Points - Bristol Myers Squibb has announced the accepted amounts and pricing terms for its tender offers to purchase outstanding notes, adjusting the maximum aggregate purchase prices for both Pool 1 and Pool 2 Notes [1][2][10] Group 1: Tender Offer Details - The maximum aggregate purchase price for Pool 1 Notes has been decreased to approximately $3.99 billion, while the maximum for Pool 2 Notes has been increased to approximately $3.51 billion [2][10] - All validly tendered Pool 1 Notes and Pool 2 Notes with acceptance priority levels 1 through 4 have been accepted for purchase, eliminating the need for proration procedures for these notes [4][10] - The 2033 Notes will be accepted on a prorated basis due to the total principal amount exceeding $250 million [4][10] Group 2: Financial Terms - The Total Consideration for each series of Notes accepted for purchase will be paid in cash, excluding accrued and unpaid interest up to the Early Settlement Date [11][12] - The Offers will expire on December 3, 2025, unless extended or terminated earlier, with the Early Settlement Date set for November 20, 2025 [10][11] Group 3: Participation and Acceptance - The withdrawal rights for the Offers expired on November 17, 2025, and all conditions of the Offers were satisfied or waived by the Early Tender Deadline [10][11] - Holders of Notes that are accepted for purchase will receive the applicable Total Consideration, while those not accepted will have their notes returned promptly [4][11]